Guselkumab Shows Efficacy for Inverse Psoriasis: Case Report
A Frontiers case report and literature review concludes guselkumab is effective for inverse psoriasis, adding IL-23 evidence to a trial-sparse phenotype.
Topic
Il 23 Inhibitor
Topic
Il 23 Inhibitor
Phase 2 Trial Tests High-Induction Risankizumab in Plaque Psoriasis
A randomized phase 2 trial in Nature tests high-induction dosing of risankizumab in moderate-to-severe plaque psoriasis, probing…
Risankizumab Tops Ustekinumab on Complete Clearance in Pediatric Psoriasis
In phase 3 OptIMMize-1 data published in the British Journal of Dermatology, risankizumab matched ustekinumab on most endpoints a…
Tildrakizumab Delivers Long-Term Control in Hard-to-Treat Psoriasis Areas
AJMC reports tildrakizumab sustained long-term psoriasis control in hard-to-treat areas such as scalp, palms and soles, strengthe…
High-Dose Risankizumab Shows Fast, Durable Psoriasis Response
Medscape reports high-dose risankizumab delivered rapid psoriasis response, with a subset of patients maintaining clearance over…
FDA Approves Icotrokinra, First Oral IL-23 Inhibitor for Plaque Psoriasis
FDA approval of icotrokinra delivers the first oral IL-23 inhibitor for plaque psoriasis, shifting a proven biologic pathway from…
Risankizumab Clears Persistent Facial Plaque Psoriasis in Case Report
A Cureus case report documents complete clearance of persistent facial plaque psoriasis with risankizumab after prior systemic th…